ReNeuron Group (LON:RENE) posted its quarterly earnings data on Friday. The company reported GBX (16.80) (($0.22)) EPS for the quarter, Digital Look Earnings reports.
ReNeuron Group stock opened at GBX 54 ($0.71) on Friday. ReNeuron Group has a one year low of GBX 1.37 ($0.02) and a one year high of GBX 142.50 ($1.86).
In other news, insider Michael Hunt acquired 7,462 shares of ReNeuron Group stock in a transaction that occurred on Thursday, September 27th. The stock was bought at an average price of GBX 67 ($0.88) per share, for a total transaction of £4,999.54 ($6,532.78).
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
See Also: Liquidity
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.